New-Onset Psoriasis Induced by Durvalumab

Area of Science:

• Oncology
• Immunodermatology

Background:

• Durvalumab is an immune checkpoint inhibitor (ICI) targeting PD-L1, used for advanced cancers.
• Immune checkpoint inhibitors can cause systemic and skin adverse events.
• Psoriasiform eruptions are known in patients with prior psoriasis history on ICIs.

Observation:

• A unique case of de novo psoriasis developed in a patient with poorly differentiated lung adenocarcinoma undergoing durvalumab treatment.
• The patient had no prior history of psoriasis.

Findings:

• The patient's de novo psoriasis responded effectively to topical therapies.
• Durvalumab treatment was continued without interruption.

Implications:

• Clinicians must recognize psoriasis as a potential adverse effect of durvalumab therapy.
• Early recognition and topical treatment can manage durvalumab-induced psoriasis, potentially avoiding treatment cessation.
• This case expands understanding of immune-related adverse events associated with PD-L1 inhibitors.